Home / Compare / Tirzepatide vs Semaglutide

Tirzepatide vs Semaglutide

Tirzepatide vs Semaglutide: how they work, doses used, FDA status and trial weight loss (20.9% vs 14.9%), with sources.

TirzepatideSemaglutide
Works onGIP + GLP-1 (dual agonist)GLP-1 only
How it is takenInjection, once weekly (Mounjaro, Zepbound)Injection weekly (Ozempic, Wegovy) or daily tablet
US statusFDA-approved (2022 diabetes, 2023 weight)FDA-approved (2017 diabetes, 2021 weight)
Highest dose15 mg weekly (label)2.4 mg weekly, or 7.2 mg (Wegovy HD, 2026)
Key trialSURMOUNT-1 (phase 3)STEP 1 (phase 3)
Average weight loss20.9% at 72 weeks (15 mg weekly)14.9% at 68 weeks (2.4 mg weekly)
Placebo in that trial3.1%2.4%

Head-to-head result

SURMOUNT-5 tested them directly: at 72 weeks, tirzepatide (up to 15 mg) gave 20.2% average weight loss vs 13.7% for semaglutide (up to 2.4 mg).

How they differ

Tirzepatide works on gip + glp-1 (dual agonist); Semaglutide works on glp-1 only. Tirzepatide is taken as: injection, once weekly (mounjaro, zepbound).Semaglutide is taken as: injection weekly (ozempic, wegovy) or daily tablet.

Dose schedules and warnings: Tirzepatide dosage chart ยท Semaglutide dosage chart.

Questions

Is tirzepatide stronger than semaglutide?
SURMOUNT-5 tested them directly: at 72 weeks, tirzepatide (up to 15 mg) gave 20.2% average weight loss vs 13.7% for semaglutide (up to 2.4 mg).
Is tirzepatide FDA-approved?
FDA-approved (2022 diabetes, 2023 weight).
Is semaglutide FDA-approved?
FDA-approved (2017 diabetes, 2021 weight).

Sources

  1. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022
  2. Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021
  3. Aronne et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM 2025

Last checked 2026-11-16. How we pick and check sources: methodology.